Skip to content

Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Inclisiran in Italy

Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Inclisiran in Italy - CHOLINET (CHOLesterol Italian Inclisiran NETwork)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06287177
Acronym
CHOLINET
Enrollment
3000
Registered
2024-02-29
Start date
2022-11-01
Completion date
2030-11-01
Last updated
2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Brief summary

Evaluation of adherence, persistence and efficacy of treatment with Inclisiran in a real-life Italian population

Interventions

DRUGInclisiran

Injection

Sponsors

Federico II University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients under Inclisiran treatment

Exclusion criteria

* Age \< 18 years o \> 80 years * Patients who refuse to participate and to sign informed consent

Design outcomes

Primary

MeasureTime frameDescription
Description of adherence to treatment with Inclisiran in a real-life Italian populationat 3 months and every 6 months thereafterAdherence will be assessed in terms of Medical Possession Ratio (MPR) which is defined as the ratio between the treatment units dispensed during the treatment period and the duration of the treatment period itself.
Description of persistence to treatment with Inclisiran in a real-life Italian populationat 3 months and every 6 months thereafterPersistence will be assessed in terms of therapeutic continuity from the start of treatment to enrollment.
Description of efficacy of treatment with Inclisiran in a real-life Italian populationat 3 months and every 6 months thereafterEfficacy of treatment will be evaluated as a change in the LDL (deltaLDL) value from the start of treatment (percentage and absolute value). The deltaLDL will be calculated as an overall (mean and median value), by type of prevention (primary and secondary), by type of basic therapy, by demographic variables (age, sex, geographic origin, basal LDL levels) and by type of prescriber (hospital or territorial).

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026